Conflicts of interest: J-H. R., V. P. S., Y. W. and K. E. L. have no conflict of interest. N. A. is an employee of SITS International, which received a grant from Boehringer Ingelheim and Ferrer for conducting the SITS-MOST and SITS-ISTR studies. E. B. is an employee of Boehringer Ingelheim GmbH, Germany. K. H. is an employee of Boehringer Ingelheim AB, Sweden. N. W. has received expenses from Boehringer Ingelheim for his role as member of the Steering Committee of the ECASS III trial, has served as a consultant to Thrombogenics as chairman of the DSMB, and has also received lecture fees from Boehringer Ingelheim and from Ferrer. SITS International (chaired by N. W.) received grants from Boehringer Ingelheim and from Ferrer for SITS-MOST and SITS-ISTR. N. W.'s institution has also received grant support toward administrative expenses for coordination of the ECASS III trial.
Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW)
Article first published online: 18 SEP 2012
© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization
International Journal of Stroke
Special Issue: World Stroke Day Edition 2014
Volume 9, Issue Supplement A100, pages 93–101, October 2014
How to Cite
Rha, J.-H., Shrivastava, V. P., Wang, Y., Lee, K. E., Ahmed, N., Bluhmki, E., Hermansson, K., Wahlgren, N. and for the SITS Investigators (2014), Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW). International Journal of Stroke, 9: 93–101. doi: 10.1111/j.1747-4949.2012.00895.x
Role of funding body: The study protocol was drafted by SITS and developed in close collaboration between SITS and Boehringer Ingelheim. All data collection and analyses were performed independently by SITS except for analysis of the rates of events in the database of pooled randomized controlled trials, which were performed by Erich Bluhmki. Boehringer Ingelheim was responsible for reporting of serious adverse drug reactions to regulatory authorities.
- Issue published online: 29 OCT 2014
- Article first published online: 18 SEP 2012
- Manuscript Accepted: 29 MAR 2012
- Manuscript Received: 16 NOV 2011
- Boehringer Ingelheim
|ijs895-sup-0001-si.pdf||63K||Appendix S1. Members of groups involved with the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-NEW).|
|ijs895-sup-0001-si.pdf||63K||Appendix S2. Algorithm used for automatic exclusion of patients from SITS-NEW and transfer to SITS-ISTR.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.